Fingolimod for the treatment of highly active relapsing–remitting multiple sclerosis

Supporting evidence

• Review decision

• Review decision - July 2013

• Appendix A - Decision paper presented to the Institute's Guidance Executive (PDF 391 KB)

  Published:

  09 July 2013